Measles virus hijacks stem cells to attack ovarian cancer
NCT ID NCT02068794
First seen Nov 18, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase trial tests a new approach for ovarian cancer that has returned after standard treatment. Doctors take stem cells from the patient's own fat tissue, infect them with a specially modified measles virus, and inject them into the abdomen. The idea is that the stem cells will carry the virus directly to cancer cells, where the virus can kill them. The study involves 34 participants and aims to find the safest dose and see if it helps control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROMUCINOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oncolytic measles virus (MV-NIS) carried by mesenchymal stem cells
What this could lead to
If it works, this could point toward a new treatment option for recurrent ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 34 participants, so it is too small to prove effectiveness. The virus may not reach all cancer cells, and side effects from the virus or stem cells are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.